Drug Profile
Beclometasone pressurised metered-dose inhaler - Chiesi
Alternative Names: BDP Modulite®; Beclazone Modulite; Beclazone Modulite Easi-Breathe; Beclojet 250 HFA; Beclometasone HFA inhalation - Chiesi; Beclometasone Modulite; Beclometasone pMDI; Beclomethasone HFA inhalation - Chiesi; Beclomethasone hydrofluoroalkane inhalation - Chiesi; Beclomethasone Modulite; CHF 781; Clenil Modulite; HFA Beclomethasone DipropionateLatest Information Update: 10 Jul 2023
Price :
$50
*
At a glance
- Originator Chiesi Farmaceutici
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Chlorinated steroids; Corticosteroids; Pregnadienetriols; Small molecules; Vascular disorder therapies
- Mechanism of Action Immunosuppressants; Steroid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Asthma
Most Recent Events
- 13 Jul 2020 Chiesi Farmaceutici and Bayer entered into a co-promotion agreement for Clenil® for Chronic respiratory diseases in China
- 29 Jan 2020 Beclometasone pressurised metered-dose inhaler is still in phase II trials for Asthma (Inhalation) is ongoing USA (NCT03084718)
- 05 Dec 2018 Chiesi Farmaceutici completes the phase II BEAM trial in Asthma in USA (Inhalation) (NCT03084718)